Biotech RadarJobs updated

COMPANY

Saol Therapeutics

HQ: Roswell, GA (US office) source · saolrx.com ↗ · Southeast

Clinical Phase 3

Keywords: neurology Pyruvate Dehydrogenase Complex Deficiency Osteoarthritis Knee Pain Spasticity Knee Pain Osteoarthritis SL-1002 SL1002 Dichloroacetate

Location: Roswell, GA (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

$115.0MRaised (2 yrs)5Trials (company is sponsor)

Timeline

  1. Raise Private placement: $115M (up to, as announced), announced Sep 15, 2026. Source: company's own press page. source ↗
  2. Trial start III: Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain source ↗
  3. Trial start II: Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain source ↗
  4. Trial start II: Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity source ↗
  5. Trial start Phase 3: Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $115.0M. Last 2 years.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07226258Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee PainIIIRecruitingNov 7, 2025Nov 30, 2026 (estimated)
NCT06931262Expanded Access Treatment Protocol With DCA for Patients With PDCDNot listedAvailableNot listedNot listed
NCT02616484Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:Phase 3Active, not recruitingJul 14, 2020Aug 27, 2025 (estimated)
NCT05311215Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb SpasticityIIUnknown status (ClinicalTrials.gov)Apr 22, 20222023-09 (estimated)
NCT05470608Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee PainIIUnknown status (ClinicalTrials.gov)Jun 13, 20222024-01 (estimated)
Feedback